

Electronic Acknowledgement Receipt

EFS ID:	7313576
Application Number:	10821718
International Application Number:	
Confirmation Number:	1509
Title of Invention:	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
First Named Inventor/Applicant Name:	Clyde L. Schultz
Customer Number:	51886
Filer:	Stephen R. Finch/Elizabeth Cullity
Filer Authorized By:	Stephen R. Finch
Attorney Docket Number:	RH01.701US
Receipt Date:	30-MAR-2010
Filing Date:	09-APR-2004
Time Stamp:	12:00:55
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$875
RAM confirmation Number	9653
Deposit Account	502121
Authorized User	FINCH,STEPHEN R

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		RH01-701US-response-for-filing093009_OA.pdf	67449 a31f29db269042a545858da005a42f81e399da6c	yes	11
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment/Req. Reconsideration-After Non-Final Reject		1	1	
	Claims		2	5	
	Applicant Arguments/Remarks Made in an Amendment		6	11	
Warnings:					
Information:					
2	Affidavit/Dec/Exhibit after Notice of Appeal	RH01-701-Lazar-Declaration.pdf	282478 39143f56c4d4637aa9d353c63aa94667a9719197	no	2
Warnings:					
Information:					
3	Affidavit/Dec/Exhibit after Notice of Appeal	RH01-701-Shultz-dec.pdf	26079 4221a471d5986ffb22a6e4c4ebafc7abab394f0c	no	1
Warnings:					
Information:					
4	Terminal Disclaimer Filed	RH01-701US-TermDisc-patent-executed.pdf	269930 100ec664b0fd25462258f0d9b4411baa4f671b95	no	2
Warnings:					
Information:					
5	Terminal Disclaimer Filed	RH01-701US-TermDisc-appln-executed.pdf	279242 13257cc684e97f06233de092705d58fd218d2d54	no	2
Warnings:					
Information:					
6	Information Disclosure Statement (IDS) Filed (SB/08)	updated_IDS.pdf	614669 140de39807e2a3fd5773a55340e52c9f9250b11e	no	6
Warnings:					

Information:					
7	NPL Documents	COLTHURST-BiomaterialsUsedinthePosteriorSegmentoftheEye.pdf	94510 a30eee6df54052240e498bacb62394b6ed5b35d1	no	1
Warnings:					
Information:					
8	NPL Documents	ZHANG-AngiogenicInhibitionMediatedbyaDNAzymeThatTargetsVascular.pdf	2039680 9d4911ae297cb19a883beb4a7353fa6c2e1813a7	no	7
Warnings:					
Information:					
9	NPL Documents	RH01-704-032009-OA.pdf	3439732 909358d8aed3a8a7cd8fbad553dd7d25d20ab716	no	27
Warnings:					
Information:					
10	NPL Documents	RH01-702-061009-FOA.pdf	887444 13748400ea8c90950851f4d9d3889de0d83f56d7	no	7
Warnings:					
Information:					
11	NPL Documents	RH01-704-110409-FOA.pdf	1447723 ba216d5b3f74e80f7a7a1d26f1124c6a83e3e6b3	no	13
Warnings:					
Information:					
12	NPL Documents	RH01-702-122409-OA.pdf	1203530 897f49d1e5d4084150ad98b57ca8d8fe9e4930bd	no	10
Warnings:					
Information:					
13	NPL Documents	Aiello-SuppressionofRetinalNeovascularizationinvivobyInhibitionofVascularEndothelial.pdf	1202450 0b7c7165f13f554e8b9184f0928b89fc6ed03d31	no	5
Warnings:					
Information:					
14	NPL Documents	Clark-AVascularEndithelialGrowthFactorAntagonistisProducedbytheHumanPlacenta.pdf	250904 0b80e3c934973c871ebb105eed327ce01aab18af	no	9
Warnings:					
Information:					
15	NPL Documents	Duh-VascularEndothelialGrowthFactorandDiabetes.pdf	371645 d1f55f103f3a015e7209fa9abb87bd94473867f4	no	8
Warnings:					

Information:					
16	NPL Documents	Flieger-DramaticImprovementinHereditaryHemorrhagicTelangiectasiaAfterTreatment.pdf	42706	no	1
			cc7ea9c6c1eb6cf2bee559a8c245e36f93e9be6		
Warnings:					
Information:					
17	NPL Documents	Hazzard-InjectionofSolubleVascularEndothelialGrowthFactorReceptor1intothePreovulatory.pdf	837864	no	8
			71eedbdb9947d0ccc2489ecc990c432df9f05a2		
Warnings:					
Information:					
18	NPL Documents	Hetian-ANovelPeptidelsolatedfromaPhageDisplayLibraryInhibitsTumorGrowthandMetastasis.pdf	433946	no	6
			bd40eb8aadcd25b1d643d6d1e0a5d007b84975e0		
Warnings:					
Information:					
19	NPL Documents	Inoue-IdentificationofaVascularEndothelialGrowthFactor-VEGF-Antagonist.pdf	306168	no	5
			d9e2fcd25e9b17eb2d40afa56df8facb0ac2c83		
Warnings:					
Information:					
20	NPL Documents	Kimura-VascularEndothelialGrowthFactorAntagonistReducesBrainEdemaFormation.pdf	406388	no	6
			d3d9ea0af814aa6ddccd4d5574099b78e966ca97		
Warnings:					
Information:					
21	NPL Documents	Ozaki-BlockadeofVascularEndothelialCellGrowthFactorReceptorSignalingIsSufficienttoCompletely.pdf	996852	no	11
			7d4b9dd39ef3a324e9324c02bc5d0117dbf7f0d1		
Warnings:					
Information:					
22	NPL Documents	Pisano-UndersulfatedLow-MolecularWeightGlycolSplitHeparinasanAntiangiogenicVEGF.pdf	269484	no	6
			7c3c57f390310118efd138d2fe3e7766470364b2		
Warnings:					
Information:					
23	NPL Documents	Siemeister-AnAntagonisticVascularEndothelialGrowthFactor-VEGF-VariantInhibitsVEGF.pdf	245096	no	5
			d964ff178fd21106334ff9f0426b15fa21a7d498		
Warnings:					
Information:					
24	NPL Documents	Soker-InhibitionofVascularEndothelialGrowthFactor-VEGF-inducedEndothelialCell.pdf	176362	no	7
			e0e225f6ad627ff1de17ca35f73301841485da79		
Warnings:					

Information:					
25	NPL Documents	deIAmo-CurrentandFutureOphthalmicDrugDeliverySystems-AShifttothePosteriorSegment.pdf	478775 c142f6781ac905aeb10b452d2a98f75e1815e98e	no	9
Warnings:					
Information:					
26	NPL Documents	Fattal-OcularDeliveryofNucleicAcids-AntisenseOligonucleotidesAptamersandsiRNA.pdf	506815 c1461042b460c2796397cd950e5f8dfbd5ba313	no	21
Warnings:					
Information:					
27	NPL Documents	Myles-RecentProgressinOcularDrugDeliveryforPosteriorSegmentDisease-EmphasisonTransscleral.pdf	383018 d06cd70c11b9ec13394e657add69d949f177dac5	no	17
Warnings:					
Information:					
28	NPL Documents	Schuch-InVivoAdministrationofVascularEndothelialGrowthFactor-VEGF-anditsAntagonist.pdf	2310962 64bbdb02016418eb5abfd579644c62d54a88c958	no	7
Warnings:					
Information:					
29	Fee Worksheet (PTO-875)	fee-info.pdf	33356 23fbff1de9bdbb9e695342e8bc4a801907cefa39	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			19905257		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					